Drugs that contain Ivacaftor; Lumacaftor
1. Orkambi patents expiration
ORKAMBI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9216969 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2026
(2 years from now) | |
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
| US10597384 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Dec, 2028
(4 years from now) | |
| US8507534 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Sep, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216969 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2026
(2 years from now) | |
| US7973038 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2026
(2 years from now) | |
| US8741933 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2026
(2 years from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US9931334 | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(2 years from now) | |
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(3 years from now) | |
| US11052075 | VERTEX PHARMS INC | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
Dec, 2028
(4 years from now) | |
| US9150552 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Dec, 2028
(4 years from now) | |
| US8653103 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Dec, 2028
(4 years from now) | |
| US10076513 | VERTEX PHARMS INC | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
Dec, 2028
(4 years from now) | |
| US8846718 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Jul, 2029
(5 years from now) | |
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(5 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(5 years from now) | |
| US9192606 | VERTEX PHARMS INC | Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Sep, 2029
(5 years from now) | |
| US8716338 | VERTEX PHARMS INC | Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Sep, 2030
(6 years from now) | |
| US8993600 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-195) | Aug 07, 2025 |
| New Patient Population(NPP) | Sep 02, 2025 |
| Orphan Drug Exclusivity(ODE-408) | Sep 02, 2029 |
| New Strength(NS) | Sep 02, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2020 |
| New Product(NP) | Aug 07, 2021 |
NCE-1 date: 03 July, 2019
Market Authorisation Date: 02 September, 2022
Treatment: Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor and ivacaftor; Method of treating cystic fibrosis in patients who a...
Dosage: GRANULE;ORAL; TABLET;ORAL
More Information on Dosage
ORKAMBI family patents
